Trevi Therapeutics Inc美股招股说明书(2026-04-17版)

PROSPECTUS SUPPLEMENT 11,600,000 Shares Common Stock We are offering 11,600,000 shares of our common stock in this offering. Our common stock is listed on the Nasdaq Global Market under the symbol “TRVI.” The last reported sale price for our common stock on April16,2026, was $14.54 per share. We are a “smaller reporting company” under applicable Securities and Exchange Commission, or the SEC, rules and, as such, have elected tocomply with certain reduced public company disclosure requirements for this prospectus supplement and future filings. See “Prospectus SupplementSummary—Implications of Being a Smaller Reporting Company” on page S-5 of this prospectus supplement for more information. Investing in our securities involves significant risks. See “Risk Factors” beginning on page S-7 of this prospectus supplement and in our filings withthe Securities and Exchange Commission that are incorporated by reference in this prospectus supplement to read about factors you shouldconsider before buying our securities. Public offering priceUnderwriting discounts and commissions(1) Proceeds to us, before expenses (1)We have agreed to reimburse the underwriters for certain offering-related expenses. See “Underwriting” beginning on page S-17 for additionalinformation regarding these expenses and the underwriting discounts and commissions payable in this offering. We have granted the underwriters an option for a period of 30 days to purchase up to an additional 1,740,000shares of our common stock at the publicoffering price per share of common stock, less underwriting discounts and commissions. If the underwriters exercise their option in full, the totalunderwriting discounts and commissions payable by us will be $10,405,200, and the total proceeds to us, before expenses, will be $163,014,800. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed uponthe accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the shares of common stock to investors on or about April 20, 2026. MorganStanley Cantor Table of Contents TABLE OF CONTENTS Prospectus Supplement ABOUT THIS PROSPECTUS SUPPLEMENTPROSPECTUS SUPPLEMENT SUMMARYRISK FACTORSCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATAUSE OF PROCEEDSDILUTIONMATERIAL U.S. TAX CONSIDERATIONS FOR NON-U.S. HOLDERS OF COMMON STOCKUNDERWRITINGLEGAL MATTERSEXPERTSWHERE YOU CAN FIND MORE INFORMATIONINCORPORATION BY REFERENCE Prospectus ABOUT THIS PROSPECTUSRISK FACTORSWHERE YOU CAN FIND MORE INFORMATIONINFORMATION INCORPORATED BY REFERENCECAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSTREVI THERAPEUTICS, INC.USE OF PROCEEDSDESCRIPTION OF DEBT SECURITIES DESCRIPTION OF CAPITAL STOCK Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and also adds to andupdates information contained in the accompanying prospectus and the documents incorporated by reference herein and therein. The second part, theaccompanying prospectus, provides more general information about our business and our securities. Generally, when we refer to this prospectus, we arereferring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement, onthe one hand, and the information contained in the accompanying prospectus or any document incorporated by reference herein or therein filed beforethe date of this prospectus supplement, you should rely on the information in this prospectus supplement. If any statement in one of these documents isinconsistent with a statement in another document having a later date — for example, a document incorporated by reference in the accompanyingprospectus — the statement in the document having the later date modifies or supersedes the earlier statement. Before buying any of the securities that we are offering, we urge you to carefully read this prospectus supplement and the accompanying prospectus, allof the information contained in the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, as well as theadditional information described under the headings “Where You Can Find More Information” and “Information Incorporated by Reference.” Thesedocuments contain important information that you should consider when making your investment decision. We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that isincorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose ofallocating risk among the parties to such agreements, and should not